VRAX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Valuation Metrics

The current forward P/E ratio for Virax Biolabs Group Ltd (VRAX.O) is -0.45, compared to its 5-year average forward P/E of -3.21. For a more detailed relative valuation and DCF analysis to assess Virax Biolabs Group Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.21

Current PE

-0.45

Overvalued PE

1.92

Undervalued PE

-8.34

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.48

Current EV/EBITDA

-0.28

Overvalued EV/EBITDA

4.26

Undervalued EV/EBITDA

-7.22

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

46.95

Current PS

74.25

Overvalued PS

163.95

Undervalued PS

-70.04

Financials

Annual

Quarterly

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

VRAX News & Events

Events Timeline

No data

News

8.5

12-04PRnewswire

Virax Biolabs Closes $5 Million Private Placement to Extend Cash Runway

8.5

12-04Newsfilter

Virax Biolabs Secures $5 Million Funding to Extend Cash Runway into 2028

2.0

12-04Benzinga

UiPath Shares Rise Approximately 9%; Check Out 20 Stocks Making Moves in Premarket Trading

People Also Watch

Frequently Asked Questions

What is Virax Biolabs Group Ltd (VRAX) stock price today?

The current price of VRAX is 0.466 USD — it has increased 2.64 % in the last trading day.

What is Virax Biolabs Group Ltd (VRAX)'s business?

Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The Company is engaged in developing ViraxImmune with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against global viral diseases as well as helping with the early diagnosis of post-viral syndromes associated with T cell exhaustion and chronic inflammation. Its product portfolio includes ViraxClear and ViraxVet. ViraxClear offers a range of accurate diagnostic testing kits and machines. ViraxVet offers various rapid and molecular tests for small animal veterinary diagnostics. The Company is initially focused on diseases associated with post-viral syndromes, including SARS-CoV-2, Human Papillomavirus (HPV), Malaria, Hepatitis B, and Herpes (HSV-1).

What is the price predicton of VRAX Stock?

Wall Street analysts forecast VRAX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for VRAX is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Virax Biolabs Group Ltd (VRAX)'s revenue for the last quarter?

Virax Biolabs Group Ltd revenue for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

What is Virax Biolabs Group Ltd (VRAX)'s earnings per share (EPS) for the last quarter?

Virax Biolabs Group Ltd. EPS for the last quarter amounts to USD, decreased % YoY.

What changes have occurred in the market's expectations for Virax Biolabs Group Ltd (VRAX)'s fundamentals?

The market is revising No Change the revenue expectations for Virax Biolabs Group Limited (VRAX) for FY2026, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -27.89%.

How many employees does Virax Biolabs Group Ltd (VRAX). have?

Virax Biolabs Group Ltd (VRAX) has 19 emplpoyees as of December 15 2025.

What is Virax Biolabs Group Ltd (VRAX) market cap?

Today VRAX has the market capitalization of 2.97M USD.